UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials

Clinical Therapeutics, 2003, Vol.25 (1), p.81-104

2003

Volltextzugriff (PDF)

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

The Lancet (British edition), 2011-11, Vol.378 (9805), p.1779-1787

2011

Volltextzugriff (PDF)

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

BMJ open, 2021-01, Vol.11 (1), p.e041479

2021

Volltextzugriff (PDF)

Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Journal of nanobiotechnology, 2023-12, Vol.21 (1), p.478-478, Article 478

2023

Volltextzugriff (PDF)

Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials

Journal of nanobiotechnology, 2024-01, Vol.22 (1), p.16-16, Article 16

2024

Volltextzugriff (PDF)

The role of optical coherence tomography in multiple sclerosis: Expert panel consensus

Journal of the neurological sciences, 2007-12, Vol.263 (1), p.3-14

2007

Volltextzugriff (PDF)

A PLACEBO RANDOMIZED CONTROLLED STUDY TO TEST THE EFFICACY AND SAFETY OF GNBAC1, A MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS – RATIONALE AND DESIGN

Multiple sclerosis and related disorders, 2016-09, Vol.9, p.95-100

2016

Volltextzugriff (PDF)

On being a neurologist in industry

Annals of neurology, 2013-03, Vol.73 (3), p.319-326

2013

Volltextzugriff (PDF)

VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis (PL5.005)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment

Muscle & nerve, 2021-11, Vol.64 (5), p.532-537

2021

Volltextzugriff (PDF)

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Multiple sclerosis, 2022-03, Vol.28 (3), p.429-440

2022

Volltextzugriff (PDF)

Use of gabapentin for postherpetic neuralgia: Results of two randomized, placebo-controlled studies

Clinical therapeutics, 2003-10, Vol.25 (10), p.2597-2608

2003

Volltextzugriff (PDF)

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

EClinicalMedicine, 2023-06, Vol.60, p.102036-102036, Article 102036

2023

Volltextzugriff (PDF)

Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease

Journal of the neurological sciences, 2021-07, Vol.426, p.117463-117463, Article 117463

2021

Volltextzugriff (PDF)

2318 Evidence for a survival benefit with long term CNM-Au8 treatment: open-label follow-up of the Australian RESCUE-ALS trial

BMJ neurology open, 2022-08, Vol.4 (Suppl 1), p.A37-A37

2022

Volltextzugriff (PDF)

2322 Results of the Australian RESCUE-ALS trial: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS

BMJ neurology open, 2022-08, Vol.4 (Suppl 1), p.A4-A4

2022

Volltextzugriff (PDF)

EDSS variability before randomization may limit treatment discovery in primary progressive MS

Multiple sclerosis, 2013-05, Vol.19 (6), p.775-781

2013

Volltextzugriff (PDF)

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch in context

EClinicalMedicine, 2023-06, Vol.60, p.102036

2023

Volltextzugriff (PDF)

Study protocol of RESCUE-ALS: A Phase 2, r andomised, double-blind, placebo-controlled study in e arly s ymptomatic amyotrophic lateral sclerosis patients to assess bioenergetic c atalysis with CNM-A u 8 as a mechanism to slow diseas e progression

BMJ open, 2021-01, Vol.11 (1), p.e041479

2021

Volltextzugriff (PDF)

Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply

The Lancet (British edition), 2012, Vol.379 (9822), p.1197-1197

2012

Volltextzugriff (PDF)

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Multiple sclerosis, 2012-08, Vol.18 (8), p.1074-1080

2012

Volltextzugriff (PDF)

Ocrelizumab in multiple sclerosis: risks and benefits/Authors' reply

The Lancet (British edition), 2012-03, Vol.379 (9822), p.1196

2012

Volltextzugriff (PDF)

Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: “Second International Workshop on Human Endogenous Retroviruses and Disease”, Washington DC, March 13th and 14th 2017

Multiple sclerosis and related disorders, 2017-07, Vol.15, p.18-23

2017

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials

Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials

The role of optical coherence tomography in multiple sclerosis: Expert panel consensus

A PLACEBO RANDOMIZED CONTROLLED STUDY TO TEST THE EFFICACY AND SAFETY OF GNBAC1, A MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS – RATIONALE AND DESIGN

On being a neurologist in industry

VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis (PL5.005)

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Use of gabapentin for postherpetic neuralgia: Results of two randomized, placebo-controlled studies

Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations (P8-8.004)

Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease

2318 Evidence for a survival benefit with long term CNM-Au8 treatment: open-label follow-up of the Australian RESCUE-ALS trial

2322 Results of the Australian RESCUE-ALS trial: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS

EDSS variability before randomization may limit treatment discovery in primary progressive MS

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionResearch in context

Study protocol of RESCUE-ALS: A Phase 2, r andomised, double-blind, placebo-controlled study in e arly s ymptomatic amyotrophic lateral sclerosis patients to assess bioenergetic c atalysis with CNM-A u 8 as a mechanism to slow diseas e progression

Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Ocrelizumab in multiple sclerosis: risks and benefits/Authors' reply

Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: “Second International Workshop on Human Endogenous Retroviruses and Disease”, Washington DC, March 13th and 14th 2017

Suchergebnisse filtern